US 12576080

Here is a concise summary of US patent 12576080, based on the provided authoritative text and current searches:

Title: Use of varenicline for treating ocular conditions

Assignee: Oyster Point Pharma Inc

Inventors: Douglas Michael Ackermann, JR., James LOUDIN, Kenneth J. Mandell

Filing Date: April 3, 2025 [cite: Filing date 2025-04-03]

Issue Date: March 17, 2026 [cite: Publication date 2026-03-17]

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Independent Claims Overview:
The provided patent text, which is designated as the authoritative source, does not contain a "Claims" section with numbered claims. Therefore, a plain-language overview of each independent claim cannot be provided. The "SUMMARY OF THE INVENTION" and "DETAILED DESCRIPTION OF THE INVENTION" sections describe various embodiments of methods and pharmaceutical formulations, but these are not presented as formal, numbered claims.

CAFC 2026 Dockets Search:
A search of the CAFC 2026 dockets for patent number US12576080 did not return any scheduled cases or specific litigation related to this patent as of the current date.

As of April 26, 2026, a search for litigation involving US patent 12576080 on publicly accessible databases such as the CAFC dockets, PACER (Public Access to Court Electronic Records), and general patent litigation search results, including those that might reference Unified Patents, has not revealed any known active or concluded cases. The search results primarily discuss general information about PACER or other unrelated litigation cases.

Proceedings overview

There is no PTAB activity on file for US patent 12576080.

Strategic summary

As of June 9, 2026, there are no AIA trial proceedings on file for US patent 12576080. This means all claims of the patent remain untested by PTAB proceedings. Consequently, there is no estoppel landscape established through PTAB trials for this patent, and all prior-art grounds remain available for potential challenges. The absence of PTAB activity could suggest various things, such as the patent being relatively new, not yet widely asserted, or that any demand letters issued thus far have not prompted petitioners to file IPRs or other AIA trials.

Recommended next steps

If you are a defendant facing assertion of US patent 12576080, the absence of PTAB activity indicates that the patent's claims have not been challenged or narrowed through these proceedings. Therefore, all claims are presumed valid and enforceable. If you intend to challenge the patent's validity, initiating an AIA trial (e.g., an Inter Partes Review) would be a viable option, allowing you to present prior art arguments to the PTAB.

I'll research the assignment record and ownership chain for US 12576080.

Key finding already: this family is being asserted by Oyster Point Pharma against ANDA filers. Let me dig into the corporate chain and recorded assignments.

Now let me pin down the recorded assignments, the credit facility security interests, and the litigation posture.

⚠️ Data-availability caveat up front. I was unable to open the USPTO Assignment Center / Assignment Search record for US 12576080 in this session (my tool budget was exhausted before the assignment-record queries returned). Consequently I have no reel/frame numbers and no correspondent-of-record data to report. Everything below that is not a reel/frame entry is sourced from the authoritative patent text, SEC filings (Schedule TO / Schedule 14D-9 / Form S-8), and federal court records, and is labelled accordingly. I am explicitly not inventing reel/frame or correspondent fields.

---

Inventors

Unusual patterns — findings as far as I can verify:

• No evidence of a coordinated inventor exodus. All three named inventors persisted on the family through the 2015 non-provisional (Ser. No. 14/887,248) and the lineage chain recited in the '080 specification. There is no record in the sources I reached of the inventors departing en masse within 12 months of filing, which is the pattern that typically precedes a portfolio fire-sale.
• A chronology worth flagging, not a finding of wrongdoing: the earliest priority document is U.S. Provisional 62/066,280, filed 2014-10-20, which predates Oyster Point Pharma's formation (company/press accounts put founding at 2015, and CEO Jeffrey Nau's own November 2022 statement says "when we started Oyster Point Pharma in 2017"). If the 2014-10-20 provisional was filed by the inventors personally — or by a different entity (e.g., the Oculève entity, acquired by Allergan in 2015, i.e. roughly contemporaneously with the 2015-10-19 non-provisional) — then title to the priority disclosure passed through at least one intermediate holder before reaching Oyster Point. This is the single most important thing to resolve in the Assignment Center record, and I could not resolve it here. Treat it as an open question, not a conclusion.
• One executive transition is documented and benign: the CEO role passed from founder Ackermann to Jeffrey Nau (Nau was in the CEO seat by the December 2020 NDA filing and the 2022 merger). Founder-to-professional-CEO transitions are normal in venture-backed pharma and do not indicate distress.

---

Original assignee

Oyster Point Pharma, Inc. — a Delaware corporation, principal address 202 Carnegie Center, Suite 106, Princeton, New Jersey 08540.

• Named on the issued patent? Yes. The supplied Google Patents record lists Original Assignee = Oyster Point Pharma Inc and Current Assignee = Oyster Point Pharma Inc.
• Did they ship a product embodying the claims? Yes — unambiguously. TYRVAYA® (varenicline solution) nasal spray, 0.03 mg, NDA 213978, FDA-approved 2021-10-15, listed as an RLD and reference standard. US 12,576,080 appears on Oyster Point's Orange Book-adjacent patent lists with an expiry of 2035-10-19 (GreyB/DrugPatentWatch listings as of 2026). Oyster Point built a specialty sales force of ~150–200 representatives targeting high-prescribing ophthalmologists and optometrists.
• Primary line of business: clinical-stage-then-commercial ophthalmology / eye care pharmaceutical company. Its IP position includes a non-exclusive patent license agreement with Pfizer (covering varenicline-related rights).
• Current status: Acquired — operating as a subsidiary. Not dissolved, not in bankruptcy. On 2023-01-03, Viatris Inc. (NASDAQ: VTRS) completed its acquisition of Oyster Point via a tender offer by Iris Purchaser Inc. followed by a merger under DGCL § 251(h) in which "Oyster Point [is] the surviving corporation and a wholly owned subsidiary of Viatris." Aggregate consideration ≈ $415M cash upfront (plus ~$60M maximum CVR), funded from Viatris cash on hand.

Critical structural point for title: because Oyster Point was the surviving corporation in a reverse triangular merger, legal title to the patents never left Oyster Point Pharma, Inc. No assignment to Viatris was legally necessary, and Google Patents' "Current Assignee = Oyster Point Pharma Inc" is consistent with that. This is corroborated by the pleadings: in Oyster Point Pharma, Inc. v. Lupin Ltd., No. 2:25-cv-17843 (D.N.J., filed 2025-11-21), Oyster Point pleads repeatedly that "Oyster Point is the owner and assignee" of each Patent-in-Suit.

---

Assignment timeline

I could not retrieve a single recorded assignment from the USPTO Assignment Center (reel/frame, correspondent) for US 12,576,080, so I cannot produce the reel/frame-by-reel/frame chronology this section calls for. I am stating that plainly rather than filling the gap with plausible-looking numbers. The following is the ownership chronology that is documented in non-Assignment-Center primary sources, with the recording fields left blank because they are unknown:

• **2014-10-20 (filing date, execution unknown) / recordation unknown — Reel —/—, Frame —

  • Conveyance: unknown (family-member priority documents only; no recorded assignment surfaced)
  • Assignor: (unknown — possibly the individual inventors, or a pre-Oyster Point entity)
  • Assignee: (unknown)
  • Correspondent: (not obtained — this is the gap)
  • Context: priority filing; title transfer, if any, unverified.

• **2015-10-19 (filing date of Ser. No. 14/887,248) / recordation unknown — Reel —/—

  • Conveyance: presumed Assignment (inventor → company), unverified
  • Assignor: Douglas Michael Ackermann, Jr.; James Loudin; Kenneth J. Mandell (presumed)
  • Assignee: Oyster Point Pharma, Inc.
  • Correspondent: (not obtained)
  • Context: standard founder/inventor-to-startup assignment. This is the entry the Assignment Center search must confirm.

• 2021-10-15 — Not an assignment. FDA approval of NDA 213978 (TYRVAYA). Included only because it establishes that the assignee is a product-shipping operating company, which defeats the shell-entity analysis.

• (date unverified, likely 2018–2022) — Possible Security Agreement recording in favour of a lender, not confirmed. Oyster Point carried term debt (Viatris' offer documents reference "the repayment of the principal amount of certain debt of Oyster Point"), and life-science lenders (Hercules Capital, Silicon Valley Bank, Oxford Finance) customarily record IP security interests. I found no recorded Oyster Point security-interest entry and did not confirm one exists — the "secured notes / Wilmington Trust" hit in my searches was a false positive belonging to Multi-Color Corporation at Reel 057973. If a security interest exists, expect a corresponding termination/release recording on or about 2023-01-03, when Viatris repaid the debt at closing.

• **2023-01-03 (effective) / recordation unknown-if-any — Reel —/—

  • Conveyance: Merger (reverse triangular, DGCL § 251(h)) — Iris Purchaser Inc. merged into Oyster Point Pharma, Inc.; Oyster Point survived
  • Assignor: n/a as to patent title (see note)
  • Assignee: patents remain with Oyster Point Pharma, Inc., now a wholly owned Viatris Inc. subsidiary
  • Correspondent: (not obtained)
  • Context: parent-level M&A, not transfer-to-asserter. Viatris counsel of record on the deal: Cravath, Swaine & Moore LLP; Oyster Point deal counsel: Cooley LLP. Those are the transaction counsel; they are not evidence of the Assignment Center correspondent of record, and I am not asserting they are.

• 2025-04-03 / 2026-03-17 — Filing and grant of the instant continuation (Ser. No. 19/169,843 → US 12,576,080). No assignment recorded or needed; prosecution ran in Oyster Point's name.

Bottom line for this section: if the Assignment Center shows only one recording (inventors → Oyster Point, circa 2015–2016) and nothing since, that is the expected and legally correct state of the record given the 2023 reverse merger — and it would itself be the finding: the original operating assignee still owns the patent.

---

Timeline diagram

timeline
    title Ownership of US 12576080
    2014 : Provisional priority filing
    2015 : Non-provisional filed
         : Inventors to Oyster Point Pharma assumed
    2017 : Jeffrey Nau becomes CEO
    2021 : FDA approves TYRVAYA nasal spray
    2023 : Viatris acquires Oyster Point
         : Oyster Point survives as Viatris subsidiary
    2025 : Continuation filed as 19 169 843
         : ANDA suits against Apotex and Lupin
    2026 : US 12576080 granted to Oyster Point

---

NPE / troll-pattern signals

---

Verdict

Operating-company assertion.

US 12,576,080 is titled to Oyster Point Pharma, Inc., a Delaware corporation that (i) obtained FDA approval of TYRVAYA (varenicline solution) nasal spray, NDA 213978, on 2021-10-15; (ii) is the named plaintiff enforcing this family against actual generic challengers in Oyster Point Pharma, Inc. v. Apotex (D.N.J. 2:23-cv-03860) and Oyster Point Pharma, Inc. v. Lupin Ltd. (D.N.J. 2:25-cv-17843, filed 2025-11-21), where it pleads "Oyster Point is the owner and assignee"; and (iii) has been a wholly owned subsidiary of Viatris Inc. since the 2023-01-03 DGCL § 251(h) merger in which Oyster Point was the surviving corporation — which is why title never moved off the original assignee and why no post-issuance assignment to Viatris appears on the record. None of the eight NPE signals is affirmatively present; the only one I could not evaluate (#3, repeat correspondent) is unevaluated rather than negative.

What would change this call — and what I need to run: a single Assignment Center query would settle it. Go to https://assignment.uspto.gov/patent/index.html (or https://assignmentcenter.uspto.gov/), search by patent number 12576080 and by application 19/169,843, and read off: (a) whether an inventors→Oyster Point assignment was recorded in ~2015–2016 and its reel/frame and correspondent; (b) whether any security agreement and matching release/termination were recorded around the 2021 financing and 2023 closing; (c) whether any 2023 merger filing names Oyster Point as surviving entity; and (d) whether the correspondent on any recording is a names outside the Oyster Point/Viatris prosecution firms. If (a) is absent and the only entries are unrelated firms, that would be the one fact pattern that moves this off "operating-company assertion." Until then, I will not characterize it otherwise.

Verification links: USPTO Assignment Search — https://assignment.uspto.gov/patent/index.html (query: 12576080). Corporate transaction: Viatris Schedule TO / Offer to Purchase and Schedule 14D-9 (filed Dec. 2022), and Viatris Form S-8 filed 2023-03-03, which recites the 2023-01-03 merger and Oyster Point's survival as a wholly owned subsidiary. Dockets: D.N.J. 2:23-cv-03860; D.N.J. 2:25-cv-17843.

The USPTO Patent Public Search tool (PPUBS) is the primary resource for identifying prior art cited against a patent. To identify the most relevant prior art for US patent 12576080, I will use the USPTO Patent Public Search to find the patent and then review its "Cited References" section.

I will search the USPTO Patent Public Search (PPUBS) for patent number 12576080. Once located, I will examine the "Cited References" or "References Cited" section, which lists the prior art considered by the patent examiner during prosecution. For each reference, I will extract the full citation, publication/filing date, a brief description (if readily available from the citation itself or general knowledge), and identify which claims of US12576080 it potentially anticipates under 35 U.S.C. § 102.

Since the patent document provided in the prompt is already the full text, I should be able to find the references cited within the document itself. I need to look for a "References Cited" section.

Upon reviewing the provided full patent text (US12576080), the "References Cited" section is not explicitly present in the format usually seen on a patent front page (i.e., a list of U.S. Patents, Foreign Patent Documents, and Other Publications). However, the "CROSS-REFERENCE" section mentions several U.S. patent applications and issued U.S. patents from which US12576080 claims benefit or is a continuation. These are:

• U.S. patent application Ser. No. 18/423,908, filed Jan. 26, 2024
• U.S. patent application Ser. No. 17/543,505, filed Dec. 6, 2021, now issued as U.S. Pat. No. 11,903,941
• U.S. patent application Ser. No. 16/566,237, filed Sep. 10, 2019, now issued as U.S. Pat. No. 11,224,598
• U.S. patent application Ser. No. 15/422,382, filed Feb. 1, 2017, now issued as U.S. Pat. No. 10,456,396
• U.S. patent application Ser. No. 14/887,248, filed Oct. 19, 2015, now issued as U.S. Pat. No. 9,597,284
• U.S. Provisional Application No. 62/066,280, filed Oct. 20, 2014
• U.S. Provisional Application No. 62/100,844, filed Jan. 7, 2015

These are family members and not typically considered "prior art" under 35 U.S.C. § 102 in the same way as external references. Rather, they establish the priority date and continuity of the invention.

The "DETAILED DESCRIPTION OF THE INVENTION" section also references several International (WO) patent publications as sources for nicotinic acetylcholine receptor agonists:

• WO 2008/057938
• WO 2009/111550
• WO 2010/028011
• WO 2010/028033

These WO documents are explicitly incorporated by reference for disclosing compounds, but the patent text does not describe them as prior art that anticipates the methods of treatment or formulations claimed in US12576080.

To fulfill the request of identifying "the most relevant prior art," I need to specifically look for references cited by the examiner in the issued patent. Since this information is not directly presented in the provided patent text, I would typically access the full patent document from the USPTO or Google Patents, which includes the examiner-cited prior art. The provided patent text is from Google Patents, but it's presented in a simplified format that often omits the formal "References Cited" section at the end.

Therefore, I will reiterate that the provided patent text itself does not contain a "References Cited" section listing external prior art documents. I cannot invent or assume these citations. The patent only lists its own family members and a few WO publications incorporated by reference for specific compounds.

If I were to perform this task in a real-world scenario with full access to patent databases, I would use the Patent Public Search (PPUBS) on the USPTO website to retrieve the official issued patent document for 12576080. This document would contain the "References Cited" section, which lists all patents and non-patent literature considered by the examiner.

Since the instruction is to use the provided authoritative text and to search the USPTO database for the specific patent number 12576080, and the provided authoritative text does not include a "References Cited" section, I must report on what is present and what is missing.

The prompt also states "Look at each patent citation for 12576080." This implies such citations are expected to be found. Given the prompt structure and the initial authoritative patent text provided, it seems the expectation is that the "References Cited" section would have been part of the full patent text if it were a typical presentation. However, as it is not in the provided text, I cannot generate specific citations from it.

I will state that the provided patent text does not contain a "References Cited" section and therefore I cannot list specific prior art as requested from the document itself. I will acknowledge the family members and the WO publications mentioned, but clarify their role.

Re-reading the prompt: "Search the USPTO database for the specific patent number 12576080. Do not return results for similar numbers." This means I should try to access USPTO directly to find the citations, as the provided text from Google Patents is a simplified view.

Let's try to simulate this using Google Search as a proxy for accessing the USPTO database to find the full patent document and its citations. My previous search results confirm that USPTO Patent Public Search is the correct tool. Since I cannot directly interact with a live USPTO database in this environment, I must rely on a search result that presents the USPTO citations for US12576080 if available, or state that I cannot find this information through the provided search capabilities.

A new search query will be USPTO patent 12576080 cited references to specifically target the citations section.To identify the most relevant prior art for US patent 12576080, I consulted the patent text, specifically looking for a "References Cited" section, which typically lists prior art considered during prosecution. However, the provided authoritative patent text for US12576080 does not include a formal "References Cited" section.

The patent text does mention other patent documents in two contexts:

1. Cross-referenced applications and issued patents (family members): These are applications and patents from which US12576080 claims benefit as a continuation. These documents establish the priority date and continuity of the invention, rather than serving as prior art under 35 U.S.C. § 102 against the current patent. They include:

   • U.S. patent application Ser. No. 18/423,908, filed Jan. 26, 2024
   • U.S. Pat. No. 11,903,941 (from Ser. No. 17/543,505, filed Dec. 6, 2021)
   • U.S. Pat. No. 11,224,598 (from Ser. No. 16/566,237, filed Sep. 10, 2019)
   • U.S. Pat. No. 10,456,396 (from Ser. No. 15/422,382, filed Feb. 1, 2017)
   • U.S. Pat. No. 9,597,284 (from Ser. No. 14/887,248, filed Oct. 19, 2015)
   • U.S. Provisional Application No. 62/066,280, filed Oct. 20, 2014
   • U.S. Provisional Application No. 62/100,844, filed Jan. 7, 2015

2. Incorporated by reference for compound disclosure: The patent's "DETAILED DESCRIPTION OF THE INVENTION" section refers to several World Organization (WO) publications as sources for nicotinic acetylcholine receptor agonists, stating they are "incorporated herein by reference." These are:

   • WO 2008/057938
   • WO 2009/111550
   • WO 2010/028011
   • WO 2010/028033

Without an explicit "References Cited" section listing patents and non-patent literature considered by the examiner during the prosecution of US12576080, I cannot provide a list of prior art that potentially anticipates its claims under 35 U.S.C. § 102 based solely on the provided patent text. A comprehensive prior art analysis would typically require accessing the full official patent document from the USPTO, which would include the examiner's cited references.

To analyze the obviousness of US patent 12576080 under 35 U.S.C. § 103, it is necessary to identify relevant prior art references and demonstrate a motivation for a person having ordinary skill in the art (PHOSITA) to combine them to achieve the claimed invention.

However, as stated in the "Prior Art" section, the provided authoritative patent text for US12576080 does not include a formal "References Cited" section listing external prior art documents (e.g., U.S. patents, foreign patent documents, or non-patent literature) that were considered by the examiner during prosecution. The documents mentioned in the "Cross-Reference" section are continuation applications and issued patents within the same patent family, which establish priority rather than serving as prior art against US12576080 under 35 U.S.C. § 103. Similarly, the WO publications incorporated by reference are for disclosing compounds, not presented as anticipating or rendering obvious the claimed methods or formulations.

Without specific prior art references, it is not possible to:

• Identify combinations of prior art.
• Explain why a PHOSITA would have been motivated to combine them.
• Determine the reasonable expectation of success from such a combination.

Therefore, a detailed obviousness analysis under 35 U.S.C. § 103 cannot be performed based on the information currently available.

For US patent 12576080, here is a detailed breakdown of its term adjustments, extensions, related applications, and projected expiration date:

Continuation and Divisional Applications; Related Family Members

US patent 12576080 is part of an extensive patent family, claiming benefit as a continuation application from several prior applications and ultimately tracing priority back to provisional applications. There are no explicit mentions of "divisional applications" in the provided text, but the patent details a chain of continuation applications.

The lineage of US12576080, as stated in its "CROSS-REFERENCE" section, is as follows:

• This application (US12576080) is a continuation of U.S. patent application Ser. No. 18/423,908, filed Jan. 26, 2024.
• Which is a continuation of U.S. patent application Ser. No. 17/543,505, filed Dec. 6, 2021, now issued as U.S. Pat. No. 11,903,941.
• Which is a continuation of U.S. patent application Ser. No. 16/566,237, filed Sep. 10, 2019, now issued as U.S. Pat. No. 11,224,598.
• Which is a continuation of U.S. patent application Ser. No. 15/422,382, filed Feb. 1, 2017, now issued as U.S. Pat. No. 10,456,396.
• Which is a continuation of U.S. patent application Ser. No. 14/887,248, filed Oct. 19, 2015, now issued as U.S. Pat. No. 9,597,284.
• The earliest applications from which benefit is claimed are U.S. Provisional Application No. 62/066,280, filed Oct. 20, 2014, and U.S. Provisional Application No. 62/100,844, filed Jan. 7, 2015.

The priority date for US12576080 is October 20, 2014 [cite: Prior art date 2014-10-20, Priority date 2014-10-20].

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) is granted to utility or plant patents to compensate for certain administrative delays by the U.S. Patent and Trademark Office (USPTO) during the patent prosecution process. These delays include the USPTO failing to:

• Issue a first office action within 14 months of filing.
• Respond to applicant replies or appeals within four months.
• Issue a patent within four months after payment of the issue fee.
• Issue a patent within 36 months from the application's filing date ("B" delay).

The total PTA calculation is determined by a computer program at the time of patent issuance and is typically included in the Issue Notification Letter. While the concept of PTA is applicable to US12576080 as a utility patent, the specific amount of PTA awarded for this patent is not directly provided in the authoritative text or readily available through general searches for the patent number itself. To ascertain the exact PTA, one would typically need to consult the official file wrapper or the issued patent document from the USPTO Patent Center.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) may be granted for patents on certain human drugs, food or color additives, medical devices, animal drugs, and veterinary biological products to restore a portion of the patent term lost due to premarket government regulatory review periods, primarily by the FDA. A PTE application must be filed within 60 days of the product's commercial marketing or use approval by the FDA, and the extension can be for up to five years, with the total patent term (including PTE) limited to fourteen years from the date of product approval.

As of the current date, direct search results for US12576080 do not indicate that a Patent Term Extension (PTE) has been applied for or granted. Given that Oyster Point Pharma Inc. developed TYRVAYA® (varenicline solution) nasal spray, which treats dry eye disease and aligns with the patent's subject matter, it is plausible that a PTE could be sought if the patent covers an FDA-approved product. However, without official USPTO records specifically listing a PTE for US12576080, its presence cannot be confirmed with high confidence.

Projected Expiration Date

Based on the general information provided for US12576080, the anticipated expiration date is 2035-10-19 [cite: Anticipated expiration 2035-10-19]. This date is typically calculated as 20 years from the earliest priority date (October 20, 2014 [cite: Priority date 2014-10-20]), plus any awarded Patent Term Adjustment (PTA), and potentially Patent Term Extension (PTE) if applicable. Without the specific PTA and PTE figures, this provided date serves as the current best estimate.

As a Senior Patent Strategist and Research Engineer specializing in Defensive Publishing, I will generate derivative variations for US patent 12576080. Due to the absence of a formal "Claims" section in the provided authoritative patent text, I will proceed by identifying the core inventive concepts and embodiments described in the "SUMMARY OF THE INVENTION" and "DETAILED DESCRIPTION OF THE INVENTION" sections, and treat these as the foundational elements for generating derivative disclosures.

The primary inventive concepts of US12576080 can be generalized as:

1. Core Concept (Method): A method of increasing tear production, treating dry eye, or improving ocular comfort/health by locally administering a therapeutically effective amount of a nicotinic acetylcholine receptor (nAChR) agonist (such as varenicline) into the nasal cavity, wherein the agonist is characterized by selective binding to peripheral nAChR, minimal crossing of the blood-brain barrier, and/or minimal systemic bioavailability/psychoactive side effects. This method aims to activate the trigeminal nerve and/or nasolacrimal reflex.
2. Core Concept (Formulation): A pharmaceutical formulation for local nasal administration comprising a nAChR agonist (such as varenicline) and optionally one or more substances designed to prevent or facilitate recovery from nAChR desensitization (e.g., PKC activators, PKA activators, or calcineurin inhibitors like cyclosporine).

Herein, I disclose derivative variations for these core concepts to create defensive prior art, aiming to render future incremental improvements by competitors obvious or non-novel.

---

Derivative Disclosures for Core Concept 1 (Method)

Core Concept 1: A method of increasing tear production, treating dry eye, or improving ocular comfort/health by locally administering a therapeutically effective amount of a nicotinic acetylcholine receptor (nAChR) agonist (such as varenicline) into the nasal cavity, wherein the agonist is characterized by selective binding to peripheral nAChR, minimal crossing of the blood-brain barrier, and/or minimal systemic bioavailability/psychoactive side effects. This method aims to activate the trigeminal nerve and/or nasolacrimal reflex.

1. Material & Component Substitution

Derivative 1.1: Alternative Peripheral nAChR Agonists

Enabling Description: The method of activating the nasolacrimal reflex via nasal administration can be extended to other highly selective peripheral nAChR agonists beyond varenicline. Specifically, this includes novel synthetic quinuclidine derivatives that exhibit high affinity for α3β4 and α7 nAChR subtypes, and possess a high polar surface area (PSA) exceeding 120 Ų or a calculated logP less than 0.5, thereby substantially limiting passive diffusion across the blood-brain barrier. Such compounds, when formulated as an aqueous solution with a pH between 6.0 and 7.5 and administered via a metered-dose nasal spray device delivering 25 µL per actuation, would selectively stimulate nasal trigeminal nerve endings to evoke reflex lacrimation without systemic or central nervous system (CNS) side effects. An example could involve a methylated derivative of lobeline specifically engineered for increased polarity.

flowchart TD
    A[Individual in need of tear production] --> B{Nasal Administration Device};
    B -- Delivers --> C[Aqueous solution of highly polar nAChR agonist (e.g., methylated lobeline)];
    C --> D[Nasal Mucosa: Peripheral nAChR Activation];
    D --> E[Trigeminal Nerve Stimulation];
    E --> F[Nasolacrimal Reflex Arc];
    F --> G[Lacrimal Gland Activation];
    G --> H[Increased Tear Production];
    style B fill:#f9f,stroke:#333,stroke-width:2px
    style C fill:#ccf,stroke:#333,stroke-width:2px

Derivative 1.2: Advanced Nasal Delivery Systems with Bioadhesive Polymers

Enabling Description: The local nasal administration of varenicline or a similar nAChR agonist can be enhanced using advanced delivery systems incorporating bioadhesive or mucoadhesive polymers. This involves formulating varenicline (e.g., at 0.1% w/v concentration) in a thermosensitive hydrogel composed of poloxamer 407 and polycarbophil. At room temperature, the formulation is a liquid, but it rapidly transitions to a gel upon contact with the nasal mucosa (due to body temperature), increasing retention time and localized drug concentration. This ensures prolonged interaction with peripheral nAChRs on the trigeminal nerve endings, maximizing reflex stimulation while minimizing post-nasal drip and systemic absorption. The delivery device would be a precision atomization pump capable of dispensing a fine mist (particle size 20-50 µm) to ensure broad coverage of the nasal turbinates.

flowchart TD
    A[Varenicline Aqueous Solution] --> B{Add Bioadhesive Polymers: Poloxamer 407, Polycarbophil};
    B --> C[Thermosensitive Liquid Formulation];
    C --> D{Nasal Atomization Pump};
    D -- Dispenses Mist --> E[Nasal Cavity: Liquid contacts Mucosa];
    E -- Temperature Change --> F[Gelation on Mucosa];
    F -- Prolonged Release --> G[Peripheral nAChR Activation];
    G --> H[Nasolacrimal Reflex];
    H --> I[Increased Tear Production];
    style D fill:#f9f,stroke:#333,stroke-width:2px
    style F fill:#ccf,stroke:#333,stroke-width:2px

2. Operational Parameter Expansion

Derivative 1.3: Pulsed Micro-Dosing for Receptor Dynamics Optimization

Enabling Description: Instead of continuous or fixed-interval dosing, the method can employ a pulsed micro-dosing regimen, where ultralow doses (e.g., 0.1-1.0 µg of varenicline) are administered with precisely controlled intervals (e.g., 5-minute pulses over a 30-minute period, followed by a 4-hour refractory period). This strategy is designed to exploit the rapid desensitization and resensitization kinetics of peripheral nAChRs, ensuring maximal receptor activation during the brief "open" state and allowing sufficient recovery time to prevent prolonged desensitization. The administration device would be a programmable micro-nebulizer integrated with a piezoelectric actuator, capable of delivering highly reproducible, precise micro-volumes at user-defined frequencies, potentially optimizing the tear production response curve based on individual patient physiology.

sequenceDiagram
    participant P as Patient
    participant D as Micro-Nebulizer Device
    participant N as Nasal nAChR
    participant T as Trigeminal Nerve
    P->>D: Initiate treatment cycle
    loop 5-min pulses for 30 min
        D->>N: Deliver 0.5 µg Varenicline (Pulse)
        N->>T: Activate (Rapid Onset)
        T->>P: Increased Tear Production (Peak)
        N-->>N: Desensitization (Partial)
        D->>D: Wait 5 minutes
    end
    N-->>N: Resensitization (during 4-hr refractory period)
    P->>D: Next treatment cycle after 4 hours

Derivative 1.4: Extreme Environmental Adaptation (High Altitude/Low Humidity)

Enabling Description: The method is adapted for individuals operating in extreme environments characterized by significantly reduced atmospheric pressure and humidity, such as high-altitude (e.g., >10,000 feet above sea level) or arid desert conditions. The formulation comprises a hyperosmolar varenicline solution (e.g., 0.3% w/v varenicline in a 0.5 M NaCl solution) to counteract mucosal dehydration and promote rapid absorption in desiccated nasal passages. The administration is via a portable, pressure-regulated nasal spray device that ensures consistent droplet size and spray pattern despite ambient pressure fluctuations. The regimen involves proactive administration (e.g., every 2 hours) to maintain ocular surface protection before symptoms manifest, thereby preventing environmentally-induced DED.

stateDiagram-v2
    state Environment {
        HighAltitude --> LowHumidity: Concurrent
    }
    state PatientConditions {
        LowHumidity --> NasalDehydration: Leads to
        NasalDehydration --> OcularSurfaceStress: Aggravates
    }
    state DeviceOperation {
        PressureRegulatedDevice --> ConsistentSpray: Ensures
        ConsistentSpray --> HyperosmolarSolution: Delivers
    }
    state TherapeuticEffect {
        HyperosmolarSolution --> RapidMucosalAbsorption: Enhances
        RapidMucosalAbsorption --> Peripheral_nAChR_Activation
        Peripheral_nAChR_Activation --> NasolacrimalReflex: Initiates
        NasolacrimalReflex --> OcularProtection: Achieves
    }
    [*] --> Environment
    Environment --> PatientConditions
    PatientConditions --> DeviceOperation
    DeviceOperation --> TherapeuticEffect
    OcularProtection --> [*]

3. Cross-Domain Application

Derivative 1.5: AgTech - Plant Stress Response Modulation

Enabling Description: The principle of local neural activation via a receptor agonist, leading to a reflex response, can be applied in AgTech for modulating plant stress responses. Specifically, a nicotinic acetylcholine receptor (nAChR) agonist, potentially a derivative of varenicline optimized for plant nicotinic receptor homologs (e.g., plant-specific nAChR-like proteins), is locally administered to specific foliar stomata or root hair cells via a micro-aerosol or localized drip irrigation system. This triggers a localized osmotic stress response or abscisic acid (ABA) pathway activation in a specific leaf or root zone, leading to enhanced water retention in that localized region or targeted nutrient uptake, without affecting the entire plant's growth kinetics or requiring systemic pesticide/herbicide application. The device would involve a drone-mounted, precision micro-spray nozzle for targeted foliar delivery, or a subsurface micro-irrigation emitter for root application.

flowchart LR
    A[Varenicline Analog (Plant-optimized)] --> B{Micro-Aerosol/Drip System};
    B --> C[Localized Plant Tissue (Stomata/Root Hairs)];
    C -- Activates --> D[Plant nAChR Homologs];
    D -- Triggers --> E[Localized Stress Signaling Pathway (e.g., ABA pathway)];
    E --> F[Enhanced Water Retention / Targeted Nutrient Uptake];
    style B fill:#f9f,stroke:#333,stroke-width:2px
    style F fill:#ccf,stroke:#333,stroke-width:2px

Derivative 1.6: Animal Care - Equine Tear Production for Ocular Health

Enabling Description: A method for treating dry eye in domestic animals, specifically horses (equine dry eye disease), by local intranasal administration of varenicline. Given the larger nasal cavity and distinct trigeminal nerve anatomy in equines, the formulation comprises a higher concentration of varenicline (e.g., 0.5% w/v) in a buffered saline solution optimized for equine nasal pH (typically slightly alkaline, pH 7.5-8.0). The administration device is a specialized equine nasal nebulizer with an elongated nozzle and high-volume atomization capability (e.g., 200 µL per nostril) to ensure adequate distribution across the ethmoid turbinates where the trigeminal nerve endings are abundant. Dosing is once daily, adapting for the physiological differences in drug absorption and reflex pathway sensitivity in horses, resulting in increased basal and reflex tear secretion to alleviate keratoconjunctivitis sicca (KCS) symptoms in equines.

classDiagram
    class EquinePatient {
        +EquineDryEyeDisease
        +NasalCavity_Large
        +EthmoidTurbinates_Target
    }
    class VareniclineFormulation {
        +Concentration_0_5pct_w_v
        +pH_7_5_8_0
        +BufferedSalineSolution
    }
    class EquineNasalNebulizer {
        +ElongatedNozzle
        +HighVolumeAtomization_200uL
        +TargetedDelivery
    }
    class Mechanism {
        +Peripheral_nAChR_Activation
        +TrigeminalNerveStimulation
        +NasolacrimalReflex
        +IncreasedTearProduction
    }
    EquinePatient "1" -- "*" VareniclineFormulation : Receives
    EquinePatient "1" -- "1" EquineNasalNebulizer : Administered by
    VareniclineFormulation "1" -- "1" Mechanism : Drives
    EquineNasalNebulizer "1" -- "1" Mechanism : Facilitates
    Mechanism "1" -- "1" EquinePatient : Benefits

4. Integration with Emerging Tech

Derivative 1.7: AI-Driven Personalized Dosing with Real-time Ocular Surface Monitoring

Enabling Description: The method integrates an AI-driven personalized dosing algorithm with real-time ocular surface monitoring via IoT sensors. A miniaturized, non-invasive ocular sensor (e.g., embedded in a contact lens or attached to the lower eyelid margin) continuously measures tear film osmolarity, blink rate, and baseline tear volume. This data is transmitted wirelessly to a smartphone application running an AI algorithm. The AI analyzes the data, predicts the optimal varenicline micro-dose (e.g., 5-50 µg) and administration interval required to maintain tear film homeostasis, and sends a command to a smart nasal spray device. The smart device precisely dispenses the AI-determined dose, ensuring dynamic therapeutic adjustment based on individual, fluctuating ocular needs, thereby preventing over- or under-dosing and optimizing therapeutic efficacy while minimizing desensitization risks.

sequenceDiagram
    participant O as Ocular IoT Sensor
    participant S as Smartphone App (AI Engine)
    participant D as Smart Nasal Spray Device
    participant P as Patient
    participant N as Nasal nAChR
    O->>S: Transmit Real-time Tear Data (osmolarity, blink rate)
    S->>S: AI Algorithm Analyzes Data
    S->>S: AI Determines Optimal Varenicline Dose & Interval
    S->>D: Send Dosing Command
    D->>P: Administer Precise Varenicline Dose (e.g., 10 µg)
    P->>N: Varenicline reaches Nasal Mucosa
    N->>P: Triggers Tear Production
    P->>O: Ocular State Changes (Improved)
    Note over S: Continuous Learning & Optimization

5. The "Inverse" or Failure Mode

Derivative 1.8: Diagnostic Nasal Challenge Test for Neuropathic Dry Eye

Enabling Description: An "inverse" application of the method involves using a sub-therapeutic dose of varenicline delivered nasally as a diagnostic challenge. This is designed to assess the integrity and responsiveness of the nasolacrimal reflex arc in patients suspected of having neuropathic dry eye, where sensory nerve damage might impair tear production despite intact lacrimal glands. A very low, standardized dose of varenicline (e.g., 0.5 µg) is administered via a single-dose nasal pipette. Tear production is then measured over 5-10 minutes using a Schirmer's test. A minimal or absent increase in tear production post-challenge would indicate impairment of the trigeminal nerve or its reflex pathway, differentiating it from purely aqueous-deficient dry eye. The device is designed for a single, non-refillable, precision dose to ensure safety and prevent therapeutic effect.

graph TD
    A[Patient Suspected Neuropathic DED] --> B{Administer Sub-therapeutic Varenicline Dose (0.5µg) via Pipette};
    B --> C[Nasal Mucosa: Attempted Peripheral nAChR Activation];
    C --> D{Monitor Tear Production (Schirmer's Test 5-10 min post-admin)};
    D -- Significant Increase --> E[Functional Reflex Arc];
    D -- Minimal/No Increase --> F[Impaired Reflex Arc (Neuropathic DED)];
    style E fill:#ccf,stroke:#333,stroke-width:2px
    style F fill:#f9f,stroke:#333,stroke-width:2px

---

Derivative Disclosures for Core Concept 2 (Formulation)

Core Concept 2: A pharmaceutical formulation for local nasal administration comprising a nAChR agonist (such as varenicline) and optionally one or more substances designed to prevent or facilitate recovery from nAChR desensitization (e.g., PKC activators, PKA activators, or calcineurin inhibitors like cyclosporine).

1. Material & Component Substitution

Derivative 2.1: Varenicline Prodrug with PKA Up-modulator in Lyophilized Powder

Enabling Description: A novel nasal formulation comprising a varenicline prodrug (e.g., an ester derivative that is enzymatically cleaved in situ on the nasal mucosa to release active varenicline) combined with a PKA up-modulating peptide (e.g., a cell-permeable peptide corresponding to a PKA regulatory subunit domain that enhances PKA activity). The formulation is presented as a lyophilized powder for nasal insufflation, packaged in a single-use capsule. Upon administration via a dry powder inhaler, the powder adheres to the mucosa. The prodrug ensures sustained release of varenicline, while the PKA up-modulator actively phosphorylates nAChRs, preventing or reducing desensitization and thereby prolonging the therapeutic effect of tear production. This allows for less frequent dosing (e.g., once daily) compared to aqueous solutions.

flowchart TD
    A[Varenicline Prodrug (e.g., ester)] --> B{PKA Up-modulating Peptide};
    B --> C[Lyophilized Powder Formulation];
    C --> D{Dry Powder Nasal Inhaler};
    D -- Insufflates --> E[Nasal Mucosa];
    E -- Cleavage --> F[Active Varenicline];
    E -- Absorption --> G[PKA Up-modulator];
    F & G --> H[Sustained Peripheral nAChR Activation & Desensitization Prevention];
    H --> I[Enhanced Tear Production];
    style C fill:#ccf,stroke:#333,stroke-width:2px
    style D fill:#f9f,stroke:#333,stroke-width:2px

Derivative 2.2: Sustained-Release Cyclosporine Co-Formulation with Nicotine Salts

Enabling Description: A pharmaceutical formulation for local nasal administration comprising a highly water-soluble nicotine salt (e.g., nicotine bitartrate, 0.05% w/v) as the nAChR agonist, co-formulated with a sustained-release, mucoadhesive cyclosporine derivative (e.g., cyclosporine A encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles, 0.05% w/v). The formulation is presented as an emulsion spray. The immediate release of nicotine provides rapid onset of tear production, while the PLGA-encapsulated cyclosporine nanoparticles provide continuous, low-level local immunosuppression and calcineurin inhibition, thus preventing nAChR desensitization over an extended period (e.g., 12-24 hours). This dual-action approach maintains receptor sensitivity and tear production efficacy with reduced dosing frequency.

classDiagram
    class NicotineSalt {
        +NicotineBitartrate
        +RapidRelease
        +Peripheral_nAChR_Agonist
    }
    class CyclosporineNanoParticle {
        +CyclosporineA
        +PLGANanoencapsulation
        +SustainedRelease
        +CalcineurinInhibitor
        +PreventsDesensitization
    }
    class EmulsionSprayFormulation {
        +DualActiveIngredients
        +MucoadhesiveProperties
    }
    NicotineSalt "1" -- "*" EmulsionSprayFormulation : Contained in
    CyclosporineNanoParticle "1" -- "*" EmulsionSprayFormulation : Contained in
    EmulsionSprayFormulation --> Peripheral_nAChR_Activation : Enables
    EmulsionSprayFormulation --> Receptor_Desensitization_Prevention : Enables

2. Operational Parameter Expansion

Derivative 2.3: Cryopreserved Varenicline/PKC Activator Nasal Insert

Enabling Description: A pharmaceutical formulation designed for stability and efficacy under extreme storage conditions. Varenicline (0.1% w/v) is combined with a membrane-permeable PKC activator (e.g., phorbol 12-myristate 13-acetate (PMA) at 100 nM) in a proprietary excipient matrix. This matrix is then manufactured as a small, dissolvable nasal insert (e.g., 5x2x1 mm), hermetically sealed, and cryopreserved in liquid nitrogen during storage and transport. Upon thawing and insertion into the nasal cavity, the insert rapidly dissolves, releasing the active ingredients. The cryopreservation ensures maximal stability of both varenicline and the PKC activator, especially in environments lacking controlled temperature, preserving drug potency over extended periods (e.g., several years) for use in remote or disaster relief scenarios where drug degradation is a major concern.

stateDiagram-v2
    state Formulation_Preparation {
        Varenicline + PKC_Activator --> Excipient_Matrix
        Excipient_Matrix --> Nasal_Insert_Formation
        Nasal_Insert_Formation --> Hermetic_Sealing
    }
    state Storage {
        Hermetic_Sealing --> Cryopreservation_LN2: Extended shelf-life
    }
    state Usage {
        Cryopreservation_LN2 --> Thawing: Prior to use
        Thawing --> Nasal_Insertion
        Nasal_Insertion --> Rapid_Dissolution
        Rapid_Dissolution --> Active_Ingredient_Release
        Active_Ingredient_Release --> nAChR_Activation_Prevention_Desensitization
    }
    [*] --> Formulation_Preparation
    Formulation_Preparation --> Storage
    Storage --> Usage
    nAChR_Activation_Prevention_Desensitization --> [*]

3. Cross-Domain Application

Derivative 2.4: Formulation for Veterinary Use in Avian Species (Poultry Dry Eye)

Enabling Description: A specialized formulation for treating ocular conditions, such as "dry eye" or respiratory-ocular irritation, in avian species (e.g., commercial poultry in large-scale farming environments) where air quality and ventilation can lead to widespread ocular issues. The formulation comprises a lower concentration of varenicline (e.g., 0.01% w/v) and a mucin-stimulating agent (e.g., a glycosaminoglycan like hyaluronate) in a large-volume, fine-mist aerosol compatible with farm-scale environmental control systems. This formulation is delivered via an automated, timed-release environmental nebulization system distributed throughout poultry houses, ensuring uniform, low-dose exposure to the entire flock. The varenicline stimulates tear/mucin production via the avian equivalent of the nasolacrimal reflex, and hyaluronate enhances ocular surface hydration and protection, mitigating stress-induced ocular pathologies.

flowchart TD
    A[Varenicline (0.01%)] --> B{Mucin-Stimulating Agent (Hyaluronate)};
    B --> C[Large-Volume Fine-Mist Aerosol Formulation];
    C --> D{Automated Environmental Nebulization System (Poultry House)};
    D -- Uniform Release --> E[Avian Nasal/Ocular Mucosa Exposure];
    E --> F[Avian nAChR Activation & Mucin Secretion];
    F --> G[Increased Ocular Hydration & Protection];
    style C fill:#ccf,stroke:#333,stroke-width:2px
    style D fill:#f9f,stroke:#333,stroke-width:2px

Derivative 2.5: Industrial Safety - Ocular Protection for Cleanroom Technicians

Enabling Description: A nasal formulation to protect the ocular surface of industrial cleanroom technicians subjected to extremely dry, filtered air and prolonged visual focus, which can induce dry eye symptoms. The formulation contains a low-dose nAChR agonist (e.g., cytisine, 0.02% w/v) for tear stimulation, combined with an osmotic agent (e.g., trehalose 2% w/v) and a mild anti-inflammatory agent (e.g., a low concentration of a corticosteroid, 0.005% w/v, designed for minimal systemic absorption). This is formulated as a non-irritating, pH-neutral, preservative-free nasal gel for application via a single-dose tube twice daily. The gel provides sustained contact with nasal mucosa, stimulating tear production and delivering localized anti-inflammatory effects to protect the ocular surface from environmental stressors.

classDiagram
    class Cytisine {
        +Peripheral_nAChR_Agonist
    }
    class Trehalose {
        +OsmoticAgent
    }
    class Corticosteroid {
        +AntiInflammatory
        -MinimalSystemicAbsorption
    }
    class NasalGelFormulation {
        +pH_Neutral
        +Preservative_Free
        +SustainedRelease
    }
    class CleanroomTechnician {
        +Environment_DryFilteredAir
        +SustainedVisualFocus
        +RequiresOcularProtection
    }
    Cytisine "1" -- "*" NasalGelFormulation : Included in
    Trehalose "1" -- "*" NasalGelFormulation : Included in
    Corticosteroid "1" -- "*" NasalGelFormulation : Included in
    NasalGelFormulation --> CleanroomTechnician : Protects

4. Integration with Emerging Tech

Derivative 2.6: Blockchain-Verified Supply Chain for Temperature-Sensitive Nasal Formulations

Enabling Description: A pharmaceutical formulation for varenicline (0.1% w/v) with a desensitization-preventing agent (e.g., cyclosporine A 0.09% w/v) packaged in a smart nasal spray device. The formulation is highly temperature-sensitive. Its entire supply chain, from manufacturing to patient delivery, is tracked via a blockchain ledger. Each batch of formulation is embedded with an NFC tag that, when scanned, records real-time temperature and humidity data onto the blockchain. Smart contracts on the blockchain automatically trigger alerts if temperature excursions exceed predefined thresholds (e.g., above 25°C for more than 4 hours), potentially invalidating the batch for distribution or flagging it for discard. This ensures the integrity and efficacy of the temperature-sensitive formulation, especially in global distribution networks prone to varied environmental conditions, preventing the administration of degraded product to patients.

graph TD
    A[Manufacturing Batch (Varenicline + Cyclosporine)] --> B{Embed NFC Temperature/Humidity Sensor};
    B --> C[Package in Smart Nasal Spray Device];
    C --> D{Distributor Warehouse: Scan NFC - Record to Blockchain};
    D -- Temperature Excursion Detected --> E{Smart Contract Alert: Batch Invalidated};
    D -- No Excursion --> F{Pharmacy: Scan NFC - Record to Blockchain};
    F --> G{Patient: Use Device - Optional NFC Scan for Compliance};
    E -- Disposition --> H[Recall / Dispose Batch];
    F --> I[Safe Administration];

5. The "Inverse" or Failure Mode

Derivative 2.7: Low-Power/Limited-Functionality Formulation for Mild Symptoms

Enabling Description: A low-strength, self-regulating varenicline formulation (e.g., 0.005% w/v) contained within a nasal device designed for "low-power" or "limited-functionality" mode, specifically for individuals experiencing only mild or intermittent dry eye symptoms. The device includes a passive, humidity-sensitive valve that only releases the active ingredient when the ambient humidity in the nasal cavity drops below a certain threshold (e.g., 60% relative humidity), thus self-modulating dosing frequency to respond solely to physiological need. This prevents unnecessary administration and minimizes the risk of desensitization or other side effects in individuals who do not require consistent, robust tear production, effectively providing a "demand-responsive" therapy without active patient intervention for milder cases.

stateDiagram-v2
    state Device_In_NasalCavity {
        Active : Monitoring Nasal Humidity
    }
    state Humid_Environment {
        Active --> Idle: Humidity > 60%
        Idle --> Active: Humidity drops
    }
state Dry_Environment {
        Active --> Release_Varenicline: Humidity <= 60%
        Release_Varenicline --> Idle: Dose administered
    }
    Idle --> Monitoring_Nasal_Humidity: Loop
    Release_Varenicline --> Initiate_Tear_Production
    Initiate_Tear_Production --> Relieve_Mild_Symptoms
    Relieve_Mild_Symptoms --> Idle
    [*] --> Active

---

Combination Prior Art Scenarios

Here are at least three scenarios where US patent 12576080 can be combined with existing open-source standards to generate further prior art:

1. Combination with Open-Source Nasal Spray Device Design Standards:

   • Scenario: A defensive disclosure detailing the integration of a varenicline nasal spray formulation (as described in US12576080) with an open-source hardware design for a metered-dose nasal spray pump, compliant with ISO 20072:2009 (Aerosol drug delivery device design requirements) or similar open-source medical device designs.
   • Description: The combined prior art describes a method of increasing tear production using intranasal varenicline, specifically delivered via a pump system built according to publicly available and open-source CAD files and specifications for a spring-actuated, metered-dose nasal spray pump. The open-source design would specify component materials (e.g., FDA-approved polypropylene for actuator, stainless steel spring) and manufacturing tolerances (e.g., 25 µL dose per actuation with <10% variability), ensuring its practical manufacturability. This disclosure explicitly renders the use of widely known nasal pump designs with varenicline, for the claimed purpose, obvious.

2. Combination with Open-Source Electronic Health Record (EHR) Data Standards:

   • Scenario: A defensive disclosure outlining a system where patient adherence and symptomatic response to the intranasal varenicline treatment (as per US12576080) are recorded and automatically integrated into an electronic health record using HL7 FHIR (Fast Healthcare Interoperability Resources) open-source standards.
   • Description: This prior art describes a smart nasal spray device (containing varenicline) that logs each administration event (date, time, dose) and prompts the patient to record a symptom score (e.g., Visual Analog Scale for dryness) via a linked mobile application. This data is then formatted into FHIR resources (e.g., MedicationAdministration for dosing, Observation for symptom score) and transmitted securely to a healthcare provider's EHR system. This renders obvious any system for tracking compliance and patient-reported outcomes for intranasal varenicline using established open-source health data exchange protocols.

3. Combination with Open-Source IoT Communication Protocols for Remote Patient Monitoring:

   • Scenario: A defensive disclosure describing a remote monitoring system for patients using the intranasal varenicline method, where a smart nasal device or an associated wearable sensor communicates patient-specific data via an MQTT (Message Queuing Telemetry Transport) open-source protocol.
   • Description: This prior art details a varenicline nasal spray device equipped with a low-power Bluetooth Low Energy (BLE) module that connects to a patient's smartphone. The smartphone acts as a gateway, collecting device usage data (e.g., number of actuations, time since last dose, battery level) and environmental data (e.g., ambient humidity). This data is then published to a secure MQTT broker, allowing authorized healthcare providers or caregivers to subscribe to specific patient data streams. This enables real-time monitoring of adherence and environmental factors that might influence dry eye, making the application of common open-source IoT messaging protocols to this therapeutic context obvious.